Galapagos NV ADR - Asset Resilience Ratio
Galapagos NV ADR (GLPG) has an Asset Resilience Ratio of 86.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Galapagos NV ADR short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Galapagos NV ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Galapagos NV ADR.
Liquid Assets Composition Over Time
This chart breaks down Galapagos NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Galapagos NV ADR long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.92 Billion | 86.45% |
| Total Liquid Assets | $2.92 Billion | 86.45% |
Asset Resilience Insights
- Very High Liquidity: Galapagos NV ADR maintains exceptional liquid asset reserves at 86.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galapagos NV ADR Industry Peers by Asset Resilience Ratio
Compare Galapagos NV ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 23.94% |
Annual Asset Resilience Ratio for Galapagos NV ADR (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Galapagos NV ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.43% | $2.91 Billion | $3.41 Billion | +11.60pp |
| 2024-12-31 | 73.83% | $3.05 Billion | $4.14 Billion | -6.90pp |
| 2023-12-31 | 80.73% | $3.52 Billion | $4.36 Billion | +4.99pp |
| 2022-12-31 | 75.74% | $3.59 Billion | $4.73 Billion | +28.18pp |
| 2021-12-31 | 47.56% | $2.47 Billion | $5.19 Billion | -5.37pp |
| 2020-12-31 | 52.93% | $3.03 Billion | $5.72 Billion | -11.65pp |
| 2019-12-31 | 64.58% | $3.92 Billion | $6.07 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $1.44 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $1.29 Billion | -- |
| 2014-12-31 | 4.66% | $12.61 Million | $270.47 Million | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more